ALK-Abello AS - Company Profile
Powered by 
All the sales intelligence you need on ALK-Abello AS in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how ALK-Abello AS fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with ALK-Abello AS.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Business Description
ALK-Abello AS (ALK), a subsidiary of The Lundbeck Foundation, develops, produces, and markets a wide range of allergy treatments, products, and services aimed at addressing the needs of allergy sufferers. ALK's primary activities include the research and development of allergy immunotherapy (AIT) treatments, diagnostics, and emergency treatments for respiratory allergies, allergic asthma, and anaphylaxis. The company serves industries related to healthcare, pharmaceuticals, and consumer healthcare.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
R&D Overview
ALK is focused on the advancement of science and innovation in allergy research, with a strong emphasis on respiratory allergy, food allergy, anaphylaxis, and adjacent therapy areas. The company implements technologies and new data platforms to accelerate its drug discovery pipeline and transform R&D processes. The R&D unit of ALK is responsible for advancing science, identifying biological pathways, and leading the discovery and development of innovative medicines within allergy and adjacent therapy areas. The unit is also tasked with implementing new technologies and data platforms to enhance drug discovery and transform R&D activities. Some of the pipeline projects of the company include peanut SLIT tablet in Phase II trial to treat peanut allergy; adrenaline autoinjector in Phase III trial to treat type 1 emergency treatment of allergic reactions; HDM SLIT tablet in research phase for the treatment of HDM allergic rhinitis; and Tree-SLIT tablet in research phase for the treatment of tree pollen allergic rhinitis. In FY2025, the company spent DKK609 million on R&D, which as a percentage of revenue stood at 9.6% and grew 14.7% YoY.
Product Categories
Overview
Other products of the company include anaphylaxis and new therapeutic areas. Some of the therapeutic areas are adrenaline autoinjector focused on emergency treatment of anaphylaxis; adrenaline nasal spray focused on the emergency treatment of anaphylaxis in the UK, Canada, and other markets; and ALK 014 (biologic).
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Overview
SCIT is an injection-based allergy vaccine. It prevents respiratory allergies from grass and tree pollen, house dust mites, and animal dander. It also acts as a preventer of severe allergic reactions due to insect stings. It offers these products in Europe and North America. SLIT drops are administered as droplets under the tongue. It offers this product in France.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Overview
It focuses on the therapeutic area of respiratory allergy and food allergy. Products include HDM SLIT-tablet; Tree SLIT-tablet; Grass SLIT-tablet; HDM SLIT-tablet; Peanut SLIT-tablet; Tree nut SLIT-tablet; and ALK 014 (biologic). HDM SLIT-tablet focuses on the therapy area of house dust mite allergic rhinitis in paediatric patients in the US and Canada; Tree SLIT-tablet focuses on the therapy area of tree pollen allergic rhinitis in paediatric patients in the EU and Canada; Grass SLIT-tablet focuses on the therapy area of grass pollen allergic rhinitis in Japan; HDM SLIT-tablet focuses on the therapy area house dust mite allergic rhinitis in China. The Peanut SLIT-tablet focuses on peanut allergy; the Tree nut SLIT-tablet focuses on tree nut allergy; and ALK 014 (biologic) on food allergy.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Geographical Segments
Target Markets
The EU, Switzerland, and Norway.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Target Markets
Japan, China, and Other Countries.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Target Markets
Canada and the US.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer